TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

AbbVie Scores Canadian Reimbursement Recommendations For Blockbuster Ulcerative Colitis Drug Skyrizi

Benzinga Logo Benzinga By Vandana Singh
AbbVie Scores Canadian Reimbursement Recommendations For Blockbuster Ulcerative Colitis Drug Skyrizi

AbbVie received positive reimbursement recommendations in Canada for Skyrizi, its ulcerative colitis drug, after successful clinical trials. The drug can now be reimbursed for adults with moderately to severely active ulcerative colitis who have not responded to previous treatments.

Insights
ABBV   positive

Received consecutive positive reimbursement recommendations for Skyrizi, completed negotiations with pan-Canadian Pharmaceutical Alliance, and reported 46.8% year-over-year sales increase for the drug in Q3 2025